Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
<p>Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screening by clinical response and changes during study tre...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849927633340465152 |
|---|---|
| author | Dwight H. Owen (15034782) |
| author2 | Brooke Benner (15054338) Lai Wei (15023852) Vineeth Sukrithan (15054341) Ashima Goyal (15054344) Ye Zhou (15054347) Carly Pilcher (15054350) Sheryl-Ann Suffren (15054353) Gwen Christenson (15054356) Nancy Curtis (15054359) Megan Jukich (15054362) Emily Schwarz (15054365) Himanshu Savardekar (15054368) Ruthann Norman (15054371) Sarah Ferguson (15054374) Barbara Kleiber (15054377) Robert Wesolowski (8863505) William E. Carson (15054380) Gregory A. Otterson (15054383) Claire F. Verschraegen (15054386) Manisha H. Shah (15054389) Bhavana Konda (15054392) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Dwight H. Owen (15034782) Brooke Benner (15054338) Lai Wei (15023852) Vineeth Sukrithan (15054341) Ashima Goyal (15054344) Ye Zhou (15054347) Carly Pilcher (15054350) Sheryl-Ann Suffren (15054353) Gwen Christenson (15054356) Nancy Curtis (15054359) Megan Jukich (15054362) Emily Schwarz (15054365) Himanshu Savardekar (15054368) Ruthann Norman (15054371) Sarah Ferguson (15054374) Barbara Kleiber (15054377) Robert Wesolowski (8863505) William E. Carson (15054380) Gregory A. Otterson (15054383) Claire F. Verschraegen (15054386) Manisha H. Shah (15054389) Bhavana Konda (15054392) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dwight H. Owen (15034782) Brooke Benner (15054338) Lai Wei (15023852) Vineeth Sukrithan (15054341) Ashima Goyal (15054344) Ye Zhou (15054347) Carly Pilcher (15054350) Sheryl-Ann Suffren (15054353) Gwen Christenson (15054356) Nancy Curtis (15054359) Megan Jukich (15054362) Emily Schwarz (15054365) Himanshu Savardekar (15054368) Ruthann Norman (15054371) Sarah Ferguson (15054374) Barbara Kleiber (15054377) Robert Wesolowski (8863505) William E. Carson (15054380) Gregory A. Otterson (15054383) Claire F. Verschraegen (15054386) Manisha H. Shah (15054389) Bhavana Konda (15054392) |
| dc.date.none.fl_str_mv | 2025-11-25T13:05:25Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30707294 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_5_from_A_Phase_II_Clinical_Trial_of_Nivolumab_and_Temozolomide_for_Neuroendocrine_Neoplasms/30707294 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer |
| dc.title.none.fl_str_mv | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screening by clinical response and changes during study treatment compared to screening in partial response (PR, orange) and stable disease (SD, green) patients. Each symbol represents one patient (n = 9). Line indicates mean.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_54ae36ce77edad2e993f353d17e42eab |
| identifier_str_mv | 10.1158/1078-0432.30707294 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30707294 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine NeoplasmsDwight H. Owen (15034782)Brooke Benner (15054338)Lai Wei (15023852)Vineeth Sukrithan (15054341)Ashima Goyal (15054344)Ye Zhou (15054347)Carly Pilcher (15054350)Sheryl-Ann Suffren (15054353)Gwen Christenson (15054356)Nancy Curtis (15054359)Megan Jukich (15054362)Emily Schwarz (15054365)Himanshu Savardekar (15054368)Ruthann Norman (15054371)Sarah Ferguson (15054374)Barbara Kleiber (15054377)Robert Wesolowski (8863505)William E. Carson (15054380)Gregory A. Otterson (15054383)Claire F. Verschraegen (15054386)Manisha H. Shah (15054389)Bhavana Konda (15054392)CancerTherapeutic Research and DevelopmentImmuno-oncologyClinical Research and TrialsChemotherapyCombination chemotherapyClinical Trial ResultsPhase II clinical trialsEndocrine-Related CancersImmunotherapyCheckpoint blockadeLung Cancer<p>Evaluation of circulating MDSC. (A) Changes in total MDSC and (B) monocytic (M-MDSC) and granulocytic (G-MDSC) subsets at cycle 1, day 15 (C1D15) compared to screening in the entire patient cohort. (C) Levels of circulating MDSC at screening by clinical response and changes during study treatment compared to screening in partial response (PR, orange) and stable disease (SD, green) patients. Each symbol represents one patient (n = 9). Line indicates mean.</p>2025-11-25T13:05:25ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30707294https://figshare.com/articles/figure/Supplementary_Figure_5_from_A_Phase_II_Clinical_Trial_of_Nivolumab_and_Temozolomide_for_Neuroendocrine_Neoplasms/30707294CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307072942025-11-25T13:05:25Z |
| spellingShingle | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms Dwight H. Owen (15034782) Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer |
| status_str | publishedVersion |
| title | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_full | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_fullStr | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_full_unstemmed | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_short | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| title_sort | Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms |
| topic | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Chemotherapy Combination chemotherapy Clinical Trial Results Phase II clinical trials Endocrine-Related Cancers Immunotherapy Checkpoint blockade Lung Cancer |